Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May 16;31(5):2856-2866.
doi: 10.3390/curroncol31050217.

Multidisciplinary and Tailored Treatment of Locally Advanced Breast Cancer in Progression during Neoadjuvant Chemotherapy: Case Report

Letizia Cuniolo  1 , Marco Gipponi  2 , Federica Murelli  1   2 , Francesca Depaoli  2 , Chiara Cornacchia  2 , Simonetta Franchelli  2 , Marianna Pesce  2 , Elena Ronda  1 , Stefano Picardi  1 , Raquel Diaz  1 , Francesca Poggio  3 , Daniele Friedman  1   2 , Franco De Cian  1   2 , Piero Fregatti  1   2
Affiliations
Case Reports

Multidisciplinary and Tailored Treatment of Locally Advanced Breast Cancer in Progression during Neoadjuvant Chemotherapy: Case Report

Letizia Cuniolo et al. Curr Oncol. .

Abstract

Locally advanced breast cancer (LABC) is a complex disease that requires a multidisciplinary approach. Neoadjuvant chemotherapy (NAC) is usually performed in order to achieve loco-regional radical resection; although its importance in the multidisciplinary approach to LABC is well recognized, a small number of patients show Progressive Disease (PD). No standard salvage treatment (ST) has been defined and different strategies can be adopted, such as second-line systemic therapies, radiation therapy, and surgery. Herein, a case of LABC in PD during NAC is reported with a literature review, with the aim of highlighting the importance of a tailored multidisciplinary treatment for each patient.

Keywords: locally advanced breast cancer (LABC); progressive disease (PD); salvage treatment (ST).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
After NAC and NART and before surgery the tumor was locally advanced, with skin ulceration and necrosis.
Figure 2
Figure 2
The specimen measured 17.5 × 12 × 5 cm.
Figure 3
Figure 3
Local state after Halsted mastectomy.
Figure 4
Figure 4
Local state after application of VAC therapy.
Figure 5
Figure 5
Re-epithelialization of wound margins after 20 days of VAC therapy.
Figure 6
Figure 6
Application of Integra® matrix.
Figure 7
Figure 7
Complete wound healing was achieved 60 days after the last surgical procedure (VRAM, local rotation flap, and a full-thickness dermo-epidermal graft taken from the medial surface of the right arm).
Figure 8
Figure 8
All the important examinations, diagnoses, and therapies are listed in this timeline.
Figure 8
Figure 8
All the important examinations, diagnoses, and therapies are listed in this timeline.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. ESO . ESMO International Consensus Guidelines for Advanced Breast Cancer ABC5. ESMO; Lugano, Switzerland: 2020.
    1. Whitman G.J., Strom E.A. Workup and Staging of Locally Advanced Breast Cancer. Semin. Radiat. Oncol. 2009;19:211–221. doi: 10.1016/j.semradonc.2009.05.006. - DOI - PubMed
    1. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Pharoah P.D., Caldas C. Cancer stem cell markers in breast cancer: Pathological, clinical and prognostic significance. Breast Cancer Res. 2011;13:6. doi: 10.1186/bcr3061. - DOI - PMC - PubMed
    1. Ma C.X., Reinert T., Chmielewska I., Ellis M.J. Mechanisms of aromatase inhibitor resistance. Nat. Rev. Cancer. 2015;15:261–275. doi: 10.1038/nrc3920. - DOI - PubMed
    1. Rugo H.S., Barry W.T., Moreno-Aspitia A., Lyss A.P., Cirrincione C., Leung E., Mayer E.L., Naughton M., Toppmeyer D., Carey L.A., et al. Randomized phase III trial of paclitaxel once per week compared with nanopar-ticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally re-current or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance) J. Clin. Oncol. 2015;33:2361–2369. - PMC - PubMed

Publication types